Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VB4-A32
- Development stage
- Preclinical
- Lead developer
- Vectus Biosystems
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VB4-A32 is a preclinical-stage, orally active small molecule drug candidate being developed by Vectus Biosystems for the treatment of liver fibrosis, including hepatitis- and metabolic dysfunction-associated steatohepatitis (MASH)-associated liver fibrosis. Derived from research into the anti-fibrotic properties of vasoactive intestinal peptide (VIP), VB4-A32 acts as a VIP mimetic and natriuretic peptide receptor C (NPR-C) agonist. In preclinical models of fatty liver disease, VB4-A32 has demonstrated the ability to significantly reduce peri-portal liver fibrosis and restore normal liver tissue architecture.
02
Targets
NPR3 (Natriuretic peptide receptor C)
Beyond the preview
Go deeper on VB4-A32.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VB4-A32.